Member Info for tqhussain

In a presentation a couple of years ago it was mentioned that Glycotest can generate $100m + annual revenue in the USA alone.

The opportunity here is huge.

Thanks Zombi, If Glycotest is a success then I see the SP going up significantly. I wouldn’t be surprised if Fosun bought the remaining share from NSCI.

Interesting listen about HCC and early detection.

https://www.onclive.com/view/screening-for-early-stage-hcc

Glycotest is a biomarker product and Amit Singal is a lead at the hospital trialing Glycotest.

Now in to $15.

This was reported by Fosun’s in the half year report ending June.

Translated from a Chinese site:

https://cj.sina.cn/articles/view/2183570524/8226a45c027012fxc?vt=4

Fosun's core competitiveness in the field of medical diagnosis. In addition, the product pipeline also includes Glycotest HCC Panel (early liver cancer diagnosis and screening program), Volition (intestinal cancer early screening and prognostic testing program) and other diagnostic products with high clinical value. We look forward to the approval of these products as soon as possible.

4.72%

PDSB in to $14.

I have reached out to the company twice in the last week but no response yet.

Lack of publicity and lack of updates from the company. With so many investment's we should be seeing regular news flow, which isn't happening.
On a positive note the company is well funded and we are in what should be a news rich period, only patience needed!

Nice to see a director taking a nibble.

Just to be clear, the below could have absolutely no relationship to Glycotest, I am just thinking out loud.

I might totally wrong here but here is an interesting article from last month.

https://www.healio.com/news/hematology-oncology/20210608/new-approvals-for-liver-cancer-mark-golden-age-of-treatment
At the bottom of the article’ The next big break’ it talks about liquid biopsy (which from what I can see is a term for blood test and that is what Glycotest is all about ) and it comes from Josep M. Llovet at Mount Sinai, who is leading the Glycotest trials.

Added a few this morning, MC looks very low while gold prices have made an upwards movement over the last few days.

NSCI is not dual listed so I doubt the USA waking up will make any difference however, PDSB share price can have an influence on this.

Another broker target of $25

I still hold and will continue to do so :)

https://proaxsis.com/proaxsis-announces-commercial-team-expansion/

PDSB flying up 15%
$11.5

https://tdameritradenetwork.com/video/rB4A-HoZE0mBehtbJF0BIA

now funded*